PR97115

CAMBRIDGE, England, July 20, 2022 /PRNewswire=KYODO JBN/

Abcam plc ("Abcam", "Company", "Group") (AIM: ABC) (Nasdaq: ABCM), a global

leader in the supply of life science research tools, today provides the

following trading update for the six-month period ending 30 June 2022.  The

Company will release its full results for the six-month period on 12 September

2022.

The Group expects to report total revenues for the six-month period of

approximately £185 million, representing 19% growth (including Biovision) at

constant exchange rates (CER)[1] and 23% on a reported basis.

Revenue growth continues to be driven by in-house catalogue sales resulting in

gross margin expansion. As the multi-year period of growth investments begins

to moderate, we anticipate delivering operating efficiencies enabling

year-over-year adjusted operating profit margin expansion consistent with the

Board's expectations.

CY2022 GUIDANCE

The Group continues to anticipate total CER revenue growth of approximately 20%

(including BioVision) with mid-teens organic CER revenue growth.

SHARE TRADING, LIQUIDITY AND LISTING

Having consulted with shareholders on options to increase share liquidity as

announced on 14 March 2022, the Board has decided to pursue a proposal to

maintain a sole listing on Nasdaq and therefore to cancel the admission of the

Company's shares to trading on AIM. The Company will continue to consult with

shareholders on this proposal in the coming weeks with the intention to put the

proposal to shareholder approval at a General Meeting called for that purpose

later this year.

[1] These results include discussion of alternative performance measures which

include revenues calculated at Constant Exchange Rates (CER) and adjusted

financial measures. CER results are calculated by applying prior period's

actual exchange rates to this period's results. Adjusted financial measures are

explained in note 2 and reconciled to the most directly comparable measure

prepared in accordance with IFRS in note 4 to the interim financial statements.

Abcam plc

+44 (0) 1223 696 000

Tommy Thomas, CPA – Vice President, Investor Relations

Numis - Nominated Adviser & Joint Corporate Broker

+ 44 (0) 20 7260 1000

Freddie Barnfield / Duncan Monteith

Morgan Stanley - Joint Corporate Broker

+ 44 (0) 207 425 8000

Tom Perry / Luka Kezic

FTI Consulting

+44 (0) 20 3727 1000

Ben Atwell / Julia Bradshaw

Note:

This trading update is based upon unaudited management accounts and has been

prepared solely to provide additional information on trading to the

shareholders of Abcam plc. All figures are provisional and subject to further

review. It should not be relied on by any other party for other purposes.

About Abcam plc

As an innovator in reagents and tools, Abcam's purpose is to serve life science

researchers globally to achieve their mission faster. Providing the research

and clinical communities with tools and scientific support, the Company offers

highly validated antibodies, assays and other research tools to address

important targets in critical biological pathways.

Already a pioneer in data sharing and ecommerce in the life sciences, Abcam's

ambition is to be the most influential company in life sciences by helping

advance global understanding of biology and causes of disease, which, in turn,

will drive new treatments and improved health.

Abcam's worldwide customer base of approximately 750,000 life science

researchers uses Abcam's antibodies, reagents, biomarkers and assays. By

actively listening to and collaborating with these researchers, the Company

continuously advances its portfolio to address their needs. A transparent

program of customer reviews and datasheets, combined with industry-leading

validation initiatives, gives researchers increased confidence in their results.

Founded in 1998 and headquartered in Cambridge, UK, the Company has served

customers in more than 130 countries. Abcam's ordinary shares are listed on the

London Stock Exchange (AIM: ABC) and its American Depositary Shares (ADSs)

trade on the Nasdaq Global Market (Nasdaq: ABCM).

For more information, please visit www.abcam.com or www.abcamplc.com 

Forward-Looking Statements

This announcement contains forward-looking statements within the meaning of the

Private Securities Litigation Reform Act of 1995. Any express or implied

statements contained in this announcement that are not statements of historical

fact may be deemed to be forward-looking statements, including, without

limitation, statements regarding Abcam's portfolio and ambitions, expected

performance for  2022 are neither promises nor guarantees, but involve known

and unknown risks and uncertainties that could cause actual results to differ

materially from those projected, including, without limitation: a regional or

global health pandemic, including the novel coronavirus ("COVID-19"), which has

adversely affected elements of our business, could severely affect our

business, including due to impacts on our operations and supply chains;

challenges in implementing our strategies for revenue growth in light of

competitive challenges; developing new products and enhancing existing

products, adapting to significant technological change and responding to the

introduction of new products by competitors to remain competitive; failing to

successfully identify or integrate acquired businesses or assets into our

operations or fully recognize the anticipated benefits of businesses or assets

that we acquire; if our customers discontinue or spend less on research,

development, production or other scientific endeavors; failing to successfully

use, access and maintain information systems and implement new systems to

handle our changing needs; cyber security risks and any failure to maintain the

confidentiality, integrity and availability of our computer hardware, software

and internet applications and related tools and functions; failing to

successfully manage our current and potential future growth; failing to

increase access in the U.S. market, which we anticipate provides greater

liquidity potential than AIM; any significant interruptions in our operations;

if our products fail to satisfy applicable quality criteria, specifications and

performance standards; failing to maintain our brand and reputation; our

dependence upon management and highly skilled employees and our ability to

attract and retain these highly skilled employees; and the important factors

discussed under the caption "Risk Factors" in Abcam's prospectus pursuant to

Rule 424(b) filed with the U.S. Securities and Exchange Commission ("SEC") on

22 October 2020, which is on file with the SEC and is available on the SEC

website at www.sec.gov, as such factors may be updated from time to time in

Abcam's other filings with the SEC. Any forward-looking statements contained in

this announcement speak only as of the date hereof and accordingly undue

reliance should not be placed on such statements. Abcam disclaims any

obligation or undertaking to update or revise any forward-looking statements

contained in this announcement, whether as a result of new information, future

events or otherwise, other than to the extent required by applicable law.

Logo - https://mma.prnewswire.com/media/1670705/Abcam_Logo.jpg 

Source: Abcam